Allelic differences in major histocompatibility complex (MHC)-encoded class II molecules affect both the binding of immunogenic peptides to class II molecules and the recognition ofMHC molecule-peptide complexes by T cells. As yet, there has been no extensive mapping of these functions to the rme structure of human class II molecules. To determine sites on the HLA-DR3 molecule involved in antigen presentation to T cells, we used monoclonal antibodies specific for HLA-DR3 to immunoselect mutants of a B-lymphoblastoid line. We located the sites of single amino acid substitutions in the HLA-DR3 molecule and correlated these structural changes with patterns of recognition by HLA-DR3-restricted, antigenspecific T cells, allospecific T cells, and allospecific anti-DR3 monoclonal antibodies. We analyzed seven mutations. One mutation, at position 74 in domain 1 of the DR j3 chain, affected recognition by all T cells tested, whereas others, at positions 9, 45, 73, 151, and 204 of the DR P chain and position 115 of the DR a chain, altered recognition by some T cells, but not others. Each of the substitutions resulted in a unique pattern of T-cell stimulation. In addition, each T-cell clone recognized a different subset of the mutants. These results indicate that different residues of the DR3 molecule are involved in presentation of antigen to different DR3-restricted T cells. These studies further show that substitutions which most likely affect peptide binding alter recognition of DR3 molecules by an alloreactive T-cell clone and some allospeciflic antibodies.
Major histocompatibility complex (MHC) molecules are highly polymorphic cell surface glycoproteins whose most evident and best understood function is to present immunogenic peptide antigens to T lymphocytes (1, 2) . In addition, allelic variation in MHC class II molecules is associated with susceptibility or resistance to autoimmune diseases (3) . The essential relationship between the polymorphism of MHC molecules and their function is well documented (4) and suggests that the locations of the hypervariable regions of MHC class II molecules are likely to identify functional domains (5, 6) . However, only a few studies have examined the particular contribution of individual class II residues to antigen presentation, in murine (7) (8) (9) or human (10) systems.
Brown et al. (11) have proposed a structural model of the class II binding domain for antigen, based on the crystal structure of an MHC class I molecule. This model identifies amino acid residues that are involved in peptide binding or in T-cell interactions based on their locations and the orientation of their side chains. One experimental approach for determining the function of individual amino acid residues, and thus testing the model's predictions, is to generate somatic cell mutants with single amino acid substitutions in class II molecules, to map their mutations, and to characterize their functional defects. Using a B-lymphoblastoid cell line (B-LCL) as progenitor, we have immunoselected mutants with single amino acid substitutions in the DR3 molecule. Here, we report seven mutant B-LCL clones in which DR3 mutations are associated with altered antigen-presenting function. We have mapped the mutations and found that changes outside as well as within the putative peptide-binding domain perturb antigen presentation by DR3 molecules. The results also suggest that the reactivities of some allospecific antibodies and an allospecific T-cell clone are sensitive to alterations in peptide binding by class II molecules.
MATERIALS AND METHODS
Antigen-Presenting Cell (APC) Lines. With the exception of mutant clones 7.25.6, 10.22.6, 7.31.6, 10.3.6, 10.77.6, and 8.39.7, the B-LCLs have been reported. Clone 8.1.6, derived from the T5-1 progenitor line (12) , is deleted for all DR and DQ A and B genes on one haplotype. Clone 8.1.6 retains expression of all HLA genes of the other (DR3) haplotype, including DRBI*0301, which encodes the A3 chain of the DR3 molecule, and DRB3*0301, which encodes the ,8 chain of the DRw52 molecule (13). Clone 9.22.3 is a homozygous DRA deletion mutant derived from 8.1.6; it lacks expression of both the DR3 molecule and the DRw52 molecule (14) . Clone 9.4.3 is an 8.1.6-derived mutant that lacks DRBI mRNA but expresses the DRw52 molecule at normal (8.1.6) levels (15) . The DR3 mutant clones 7.25.6, 10.22.6, 7.31.6, 10.3.6, and 10.77.6 were isolated from 8.1.6 by ethyl methanesulfonate mutagenesis, then immunoselection with anti-DR3 monoclonal antibody (mAb) 16.23, followed by complement-mediated lysis. Conditions for immunoselection with mAb 16.23 have been described (14) . Mutant 8.39.7 was isolated by the same protocol, using a different anti-DR3 mAb, CD6.B1 (16) . Clone 7.13.6, a previously described DR3 point mutant, was also isolated by 16.23 immunoselection (10) .
Sequence Analysis of Mutant DRA and DRB Genes. Cytoplasmic RNAs were prepared from mutant cells by guanidine hydrochloride extraction, and poly(A)+ mRNA was separated on an oligo(dT)-cellulose minicolumn (17 (New England Biolabs) in a standard second-strand reaction (18) . After phenol/chloroform extraction and ethanol precipitation, the cDNA was suspended in 50 t1 of 10 mM Tris, pH 7.5/1 mM EDTA and 1/10th of the volume was used for amplification by the polymerase chain reaction (PCR). For amplifications ofDRBJ, primers B12 (plus strand, 5' untranslated region, 5'-GTCGACCCTGGTCCTGTCCTGTTCTCC-3') and B14 (minus strand, 3' untranslated region, 5'-AAG-AATAACAGCCAGGAGGGAAAGCTT-3') were used. For amplification of DRA, primers were A10 (plus strand, 5' untranslated region, 5 '-GTCGACACTCCCAAAAGA-GCGCCCAA-3') and All (minus strand, 3' untranslated region, 5'-AAGCTTTAAGAAACACCATCACCTCC-3') were used. After 25 cycles of denaturing at 940C, annealing at 550C, and elongation at 720C, the reaction mixture was loaded onto a 2 x 3-inch (1 inch = 2.54 cm), 11-ml minigel and electrophoresed for 15 min at 80 V. After staining with ethidium bromide, the prominent band of the predicted size was excised and the DNA was recovered by using a silica matrix system (Bio 101, La Jolla, CA). For a sequencing reaction, 1/10th of the amount recovered was subjected to dideoxy sequencing using modified T7 DNA polymerase (Sequenase, United States Biochemical). The PCR primers and additional oligonucleotide primers covering 21-base-pair segments of the coding regions or its inverse complement were used to generate 100-to 300-base segments of sequence information, resulting in the complete sequence of the coding regions. The complete coding sequences of the DRA and DRBI*0301 genes from 8.1.6 are identical to sequences reported previously (10, 19, 20 (24) .
T-Cell Proliferation Assays. Human T-cell lines specific for soluble protein antigen were generated as described (25) . The antigens tetanus toxoid (TT), purified protein derivative of Mycobacterium tuberculosis (PPD), and hepatitis B surface antigen (HBsAg) were used as described (10, 25) . Antigenspecific T-cell clones were obtained by standard methods of limiting-dilution cloning in the presence of antigen, exogenous interleukin 2, and irradiated peripheral blood mononuclear cells as APC. The gp350/DR3 clone is specific for a major envelope glycoprotein of Epstein-Barr virus (B.C., unpublished work). The allospecific, anti-DR3 clone was isolated as described (26) . T-cell clones are designated by antigen/restriction element. The restriction element used by a T-cell clone was identified by comparing the stimulation observed with a panel of class II antigen-loss mutants derived from 8.1.6, as described (25) . For (28) .
Localization of DR (3-and a-Chain Substitutions on a Model of Class II Molecular Structure. To locate the positions of the seven mutations on a structure that approximates the folded DR3 molecule, we identified residues of HLA-A2 that correspond to the mutant DR3 positions and located them in the class I molecular structure (Fig. 1 Upper) (29) . Mutations in the antigen-binding domain were also located on the Brown and Wiley model of class II molecular structure (Fig. 1 Lower) (11) (Table 2) ; data from mutant 7.13.6, previously reported (10) , are also shown.
Most of the Mutants Have Selective Defects in Antigen Presentation. To evaluate the capacity of the mutant DR3 molecules to act as restricting elements for antigen-specific T cells, we examined the ability ofthe DR3 mutants to stimulate a panel of DR3-restricted T cells specific for different soluble antigens (Table 3 ). Only one of the substitutions, at position 74 of DRB (mutant 8.39.7), disrupts antigen presentation to all of the DR3-restricted T cells assayed. This profound effect results from the DRBI mutation in 8.39.7, and not from a generalized abnormality of antigen processing and presentation, as this mutant stimulates normal proliferation of T cells restricted by DRw52 and DP4. In contrast, the mutations in 7.13.6, 7.31.6, 10.22.6, 10.3.6, and 10.77.6 result in selective defects in DR3-restricted presentation. Each mutation is associated with a unique pattern of T-cell stimulation. The mutations in 7.13.6 and 7.31.6 ablate presentation to one antigen-specific, DR3-restricted clone (PPD/DR3), but allow normal presentation to several other T cells. Mutant 10.22.6 cannot stimulate one DR3-restricted, PPD-specific clone, stimulates the gp350-specific clone to a lower level than progenitor 8. Under the conditions of these assays, the observed defects in antigen-specific T-cell stimulation derive primarily from the qualitative, rather than quantitative, changes in the mutant DR3 molecules; defects in the presentation of soluble antigens observed with mutant APCs were not overcome by doubling the number of APCs used (data not shown). Moreover, each antigen-specific T-cell clone was stimulated effectively by at least one mutant APC line with decreased cell surface expression of DR3 molecules, indicating that these levels were sufficient for effective stimulation. ND, not determined. *Two levels of APCs were used to stimulate the alloreactive T-cell clone: 1x, 50,000 B-LCL stimulators; 2x, 100,000 B-LCL stimulators. tSimilar data with TT-and PPD-specific T cells were previously reported (10) .
nature of the presentation defects associated with mutations at positions 9, 45, 73, and 151 of DR,3 and 115 of DRa indicate that different residues are involved in DR3-restricted presentation to different T cells.
Stimulation of an Alloreactive T-Ceil Clone Is Affected by
Quantitative and Qualitative Changes in DR3 Expression. To evaluate whether the residues altered in the mutants are involved in the stimulation of an alloreactive response, we tested the ability of the mutants to stimulate an anti-DR3 T-cell clone (Table 3 ). Mutants 10.3.6, 10.77.6, and 7.25.6, all of which express decreased levels of DR3 molecules, each stimulate the allospecific anti-DR3 clone approximately in proportion to the level of DR3 molecules on the cell surface. In each case, increasing the number of mutant APCs increases the T-cell stimulation (Table 3) . Thus, it appears that the altered stimulation of the allospecific T-cell clone by mutants 10.3.6, 10.77.6, and 7.25.6 derives, in large part, from their altered levels of cell surface DR3 molecules. Mutants 8.39.7 and 7.13.6, on the other hand, are unable to stimulate the alloreactive clone, even if the number of APCs is increased (Table 3) , and despite the fact that, in 8.39.7, the cell surface abundance of DR3 molecules is normal ( Table 2 ). The inability of increased numbers of 8.39.7 and 7.13.6 cells to stimulate the alloreactive clone suggests that the residues altered in these mutants are critical for recognition by the alloreactive clone.
DISCUSSION
Analyses of structure-function relationships in MHC molecules are likely to reveal general rules governing MHCpeptide-T cell interactions as well as variations arising from species and allelic differences in MHC molecules. Identification of the unique features of particular MHC molecules may also be important for understanding the association of certain MHC alleles, such as HLA-DR3, with autoimmune disease. We have begun to dissect the relationship of fine structure to antigen presenting function in the DR3 molecule.
In the present paper, we examine seven mutant cell lines with different point mutations in the DR3 molecule. Two salient points emerge from the analyses of the functional effects of these single amino acid substitutions. First, different residues of the DR3 molecule appear to be involved in presentation to different DR3-restricted T cells. Each mutation results in a unique pattern of stimulation of the T-cell clones, and each DR3-restricted T cell clone is stimulated by a different subset of the mutants. This complex relationship of fine structure to antigen-presenting function has been a consistent finding among the murine and human MHC class I and class II molecules examined to date (8, (30) (31) (32) (33) (34) (35) (36) (37) (Table 2) . A direct role in antigen presentation for position 74 is consistent with the predicted functional importance of polymorphic residues. Not all changes in polymorphic residues have the effect of the change at position 74, however. The substitution at polymorphic position 9, which also alters charge, has a more modest effect. Profound effects on T-cell recognition, like those observed with the mutation at position 74, have also been observed in I-A,8 mutants with substitutions at other polymorphic residues in this region of the p-chain a-helix (35, 36) .
In (30, 31, 37) . These interpretations must be qualified, however, by uncertainty regarding both the overall structure of class II molecules (11) and the positions of amino acid side chains in particular class II alleles (38) . As an alternative approach to defining the nature of the ligand of alloreactive TCRs, we have studied allostimulation by mutant APCs that are unable to generate class II-peptide complexes from soluble antigens (39) . Three of four alloreactive T-cell clones fail to recognize these antigen-processing mutants, even though their class II molecules are of normal primary structure and abundance on the cell surface (T. Cotner, E.M. and D.P., unpublished work). These two and other lines of evidence (40) 
